DavidVanderstraeten

Associate

Brussels + 32.2.645.14.10

David Vanderstraeten advises and represents Belgian and foreign companies on all aspects of corporate law, with a focus on M&A, private equity and venture capital transactions, and corporate restructurings and reorganizations.

Recent key representations include the acquisition of HistoGeneX and Caprion Biosciences by Arsenal Capital Partners, the Series B financing round of Qover SA led by Alven Capital, and the acquisition of the Bricsys group by Hexagon.

Prior to joining Jones Day in 2018, David worked for another international law firm, where he gained experience in the banking and financial regulation area.

Experience

  • Furukawa Electric and Superior Essex global joint venture finalizedJones Day advised Furukawa Electric Co., Ltd. in its finalization of a global joint venture with Superior Essex Inc.
  • Beerschot arbitrates various decisions taken following termination of football competition in light of COVID-19 crisisJones Day successfully represented KFCO Beerschot-Wilrijk NV, a Belgian football club in multiple arbitration proceedings before the Belgian Arbitration Tribunal for Sports against the Royal Belgian Football Association and the Pro League in relation to decisions taken following the termination of the Belgian football competition in light of the COVID-19 crisis, thereby facilitating its promotion to competition 1A.
  • Cowboy raises capital in Series B roundJones Day represented Cowboy SA, a Belgian start-up that developed an innovative electric bike for the modern-day commuter, in connection with its issuance of Series B Convertible Preferred Stock in a private placement to Exor Seeds, HCVC, Index Ventures, Isomer Capital, and Future Positive Capital.
  • PolyOne acquires Clariant color and additive masterbatch business for $1.5 billionJones Day advised PolyOne Corporation in the $1.5 billion purchase of Clariant’s global color and additive masterbatch business.
  • ETF Partners invests in IntigritiJones Day represented ETF Partners in connection with its €4 million Series A investment in Intigriti.
  • Freudenberg acquires Low & Bonar PLCJones Day represented Freudenberg SE, the global technology group, in connection with the £107 million takeover offer by group member, FV Beteiligungs-GmbH, of Low & Bonar PLC via a Scheme of Arrangement.
  • Rising Point Capital acquires Conco HoldingsJones Day advised Rising Point Capital, LLC in its acquisition of Conco Holdings, a provider of low-pressure, mechanical heat exchanger tube cleaning and non-destructive testing services.
  • Western Digital sells ActiveScale™ business to QuantumJones Day advised Western Digital Corporation's subsidiary Western Digital Technologies, Inc. in the sale of its ActiveScale™ business to Quantum Corporation.
  • Proxyclick raises $15 million in financing roundJones Day advised Proxyclick, a software creator for visitor registration and management, in its $15 million Series B financing round led by Five Elms.
  • Hi Inov participates in Series B financing round of Customs4TradeJones Day advised Hi Inov in connection with the Series B round of financing of Customs4Trade NV, a Belgian company developing software for customs and trade management.
  • BLACKB sells Darts-ip to Clarivate AnalyticsJones Day represented the various shareholders of BLACKB in the sale of all their shares to the Belgian subsidiary of the U.S. listed company Clarivate Analytics (US) LLC.
  • Western Digital sells IntelliFlash™ business to DataDirect Networks, Inc. (DDN®)Jones Day advised Western Digital Corp. in the sale of its IntelliFlash™ business to DataDirect Networks, Inc. (DDN®), a global leader in artificial intelligence (AI) and multi-cloud data management.
  • AURELIUS sells Solidus Solutions for €330 million (US$375.6 million)Jones Day advised AURELIUS Equity Opportunities SE & Co. KGaA on the full shop auction sale of the Solidus Solutions group to funds advised by Centerbridge Partners, L.P.
  • Arsenal Capital Partners acquires HistoGeneX and Caprion BiosciencesJones Day advised Arsenal Capital Partners on major investments in HistoGeneX and Caprion Biosciences and the subsequent combination of the two businesses.
  • Arsenal Capital Partners acquires Seal for Life Industries from Berry Global Group Inc. for $328 millionJones Day advised Arsenal Capital Partners on the $328 million acquisition of Seal for Life Industries from Berry Global Group Inc.
  • Alven Capital participates in Series B financing round of QoverJones Day advised Alven Capital SA, as lead investor, in connection with the Series B financing round of Qover SA, a Belgian insurtech company that builds their own insurance products and makes them available in real-time through open APIs.
  • Gimv invests in Coolworld RentalsJones Day advised Gimv in its acquisition of a majority shareholding in fast-growing Coolworld Rentals, a full-service renter of cooling and heating equipment.
  • Essilor acquires Brille24Jones Day advised Essilor International in the acquisition of 100% of Brille24 GmbH, one of the leading online retailers of optical products in Germany.
  • UPL acquires Arysta LifeScience from Platform Specialty Products Corporation for $4.2 billionJones Day advised UPL Limited ("UPL"), a leading global generic agrochemical company based in India, in connection with its subsidiary, UPL Corporation Limited’s, US$4.2 billion acquisition and related $3 billion term financing of Arysta Lifescience Inc. (“Arysta”), a global provider of crop protection solutions, including bio-solutions and seed treatment, from NYSE listed Platform Specialty Products Corporation (“Platform”).
  • Cowboy raises capital in Series A roundJones Day represented Cowboy SA, a Belgian start-up that developed an innovative electric bike for the modern-day commuter, in connection with its issuance of €10 million (US$11.4 million) of Series A Convertible Preferred stock in a private placement to Tiger Global Management, Index Ventures, and Hardware Club.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.